Company news
Imugene Ltd (ASX:IMU) news
Imugene Ltd news releases on 6ix. Latest, Oct 17, 2017: Response to ASX Price Query
Press releases — page 5
Response to ASX Price Query
October 16, 2017
IMU Receives $1.1m R&D Tax Refund
October 10, 2017
First Patient Dosing Commences of HER-Vaxx
August 30, 2017
Imugene granted Canadian patent for Her-Vaxx cancer vaccine
July 21, 2017
Appendix 4C - quarterly and Commentry Q3
April 28, 2017
IMU Raises $3.0m from Options Plan
April 6, 2017
$1.35 million Options Underwritten
March 29, 2017
Half Year Report and Accounts
February 28, 2017
Intellectual Property Strengthened Around Lead Clinical Drug
February 26, 2017
BMC Cancer journal publishes encouraging HER-Vaxx research
February 12, 2017
Imugene progresses mimotope platform
December 18, 2016
Response to ASX Aware Query
December 15, 2016
Acquisition of immuno-oncology technology
December 12, 2016
Leslie Chong Appointed Chief Executive Officer
November 21, 2016
Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study
November 6, 2016
Imugene Share Placement raises $3.2 million
October 20, 2016
Imugene receives $1.3m R&D Tax Refund
September 22, 2016
Imugene successfully completes preclinical animal studies
September 19, 2016
Imugene Final Cancer Vaccine Doses Delivered to GMP Depot
August 29, 2016
Imugene Receives Approval to Start Gastric Cancer Study
August 21, 2016
Imugene Receives Institutional Review Board approval
August 10, 2016
Imugene Receives Institutional Review Board Approval
July 10, 2016
Regulatory package submission for Her-Vaxx in Hong Kong
April 21, 2016
Imugene Announces Successful Capital Raising
March 30, 2016
Manufacturing Update
March 7, 2016
Partnership to Develop Mimotope Immuno-Oncology Platform
February 11, 2016
Imugene key HER-Vaxx patent granted in Europe
February 10, 2016